Skip to content Skip to footer
Subscribe Now
VIEWPOINTS

Unlocking Approval: Christophe Piketty from Galderma in an Illuminating Conversation with PharmaShots 

Shots:   Backed by positive results from the P-III ARCADIA study, Galderma’s Nemluvio recently received approval from the US FDA for patients with moderate to severe atopic dermatitis  Nemluvio (nemolizumab) has previously been approved for the treatment of prurigo nodularis  Christophe Piketty, VP, Head of Innovation, Therapeutic Dermatology, Global Clinical Sciences, Galderma, highlighted insights from the…
June 30, 2025

Read more

Galderma
NEWS

Galderma Initiates P-II Studies of Nemolizumab for Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO)

Shots: Galderma announced the initiation of two P‑II clinical studies evaluating the efficacy and safety of nemolizumab in pts with SSc and CPUO Patient enrollment for both studies is planned to start in H2’25, with expected completion in 2028 for SSc and in 2026 (US) for CPUO Nemolizumab is a mAb targeting the IL‑31 receptor…
June 26, 2025

Read more

Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots
VIEWPOINTS

Chronic Dermatologic Care: Baldo Scassellati Sforzolini from Galderma in Conversation with PharmaShots

Shots:  Recently, the groundbreaking results from Galderma’s Phase III OLYMPIA 1 trial were published in JAMA Dermatology. The study evaluated nemolizumab in patients with moderate-to-severe active prurigo nodularis  The trial met all primary and secondary endpoints, with results aligning with those from the OLYMPIA 2 trial, reinforcing nemolizumab’s potential in achieving sustained improvements in the…
May 26, 2025

Read more

Galderma
NEWS

Galderma’s Nemluvio (Nemolizumab) Receives Positive CHMP Opinion to Treat Prurigo Nodularis (PN) and Atopic Dermatitis 

   Shots:    The CHMP's recommendation of Nemluvio (SC) for mod. to sev. atopic dermatitis (≥12yrs.) & prurigo nodularis in eligible ones for systemic therapy was based on P-III ARCADIA & OLYMPIA studies, respectively. Reviews are ongoing in Australia, Singapore, Switzerland, Canada, Brazil & South Korea, with more filings underway   ARCADIA 1 & 2 studies assessed…
December 13, 2024

Read more

Viewpoints_Baldo Scassellati Sforzolini
VIEWPOINTS

Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots:  Galderma’s Nemluvio (nemolizumab) was recently approved by the US FDA for the treatment of adults with prurigo nodularis, following positive Phase III results from the OLYMPIA study.  Today at PharmaShots, we have Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma, to discuss the study’s design and the potential of Nemluvio in…
October 23, 2024

Read more

Viewpoints_Christophe Piketty
VIEWPOINTS

Fingers Crossed: Christophe Piketty from Galderma in a Stimulating Conversation with PharmaShots

Shots:  Atopic dermatitis remains one of the most common inflammatory skin diseases, affecting more than 230M people across the globe. Characterized by frequent itching and recurrent skin lesions, atopic dermatitis is a chronic condition  Recently the Lancet published data from Galderma’s P-III trial, ARCADIA 1 and ARCADIA 2, demonstrating the potential of nemolizumab to improve skin…
September 11, 2024

Read more